EN DE
Watch Evolus Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Evolus Inc (EOLS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Evolus Inc stock $7.33, price $6.81, upside +7.6%, quality 40 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EI Evolus Inc logo Thin data Nov 11, 2026

Evolus Inc

EOLS · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value $7.33 · Fairly valued
Quality 40/100
Mixed Growth (revenue 5y +39.4 %/yr in USD)
Negative equity (buybacks among others)
Mixed vs. peers (3/7)
Insiders sold $950,176 (6M)
Loss-making · -9.6% net margin (TTM)
Negative free cash flow
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch Evolus Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$17.49 $3.94 Fair Value $7.33 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $3.94 – $17.49 · fair‑value band $5.50 – $9.16 · the $6.81 price screens below the $7.33 fair value. As of Nov 11, 2026.

Follow Evolus in your weekly email

Every Wednesday you see whether Evolus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.

Show moreShow less

It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Stock analysis

Evolus Inc (EOLS) currently trades at $6.81, while our estimate is $7.33, so the stock looks roughly fairly valued today (gap 7.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.50 (bear) to $9.16 (bull), the price of $6.81 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Evolus Inc reported revenue of $297M in FY2025 versus $99.7M in FY2021, a compound +31.4%/yr. Reported net income was −$51.6M in FY2025.

Key figures

Market cap $449M Small · P/S ratio 1.42 · EPS (TTM) $−0.4800 · Net margin −9.6% · Return on equity −18,730% · Return on assets (EBIT) −22.3% (5-year average) · Operating margin −7.4% · Revenue (TTM) $325M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 73% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 8%, EOLS screens cheaper than that median.

Fair Value

Bear $5.50 Fair Value $7.33 Bull $9.16
Price $6.81 · Upside +7.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 50
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 27
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 18
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 46
Distance to the 52-week high, does not count
New shares 44
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $950,176 and none bought.

  • SaleDavid MoatazediOfficer, Director4× since Dec 22, 2025: 246,036 shares, avg. $6.75$1.7MSep 2, 2026
  • SaleRui AvelarOfficer3× since Dec 22, 2025: 35,376 shares, avg. $5.02$177,662Mar 20, 202610b5-1 plan

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−270.7% (2020) → −12.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch EOLS, get fair value alerts →

Compare Evolus Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside +7.6% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −22.9% · Bottom 25%
Net margin (12 months) −9.6% · Bottom 25%
Operating margin (12 months) −7.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 13.0% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 1.38× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)43 · sector 18
FUTURE (revenue growth)65 · sector 24
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.32 $113.53 +38% vs EOLS
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs EOLS
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs EOLS
Haleon plc HLN $8.97 $8.62 −4% vs EOLS
Merck KGaA MRK €149.35 €109.18 −27% vs EOLS
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs EOLS
Takeda Pharmaceutical Company TAK $21.09 $11.31 −46% vs EOLS
Teva Pharmaceutical Industries Limited TEVA $42.97 $20.74 −52% vs EOLS
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs EOLS
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs EOLS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Evolus Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Evolus Inc Fair Value". https://www.fairvalue-calculator.com/stock/EOLS

Frequently asked questions

Is Evolus Inc (EOLS) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $7.33 versus a price of $6.81, about +8% upside (fairly valued).
What is the fair value of EOLS?
Our estimate for Evolus Inc is $7.33 (as of Nov 11, 2026), built from audited fundamentals. The current price: $6.81.
What is the quality score of EOLS?
Evolus Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evolus Inc (EOLS)?
Our calculated price target is the estimate of $7.33 (as of Nov 11, 2026). Cautious scenario $5.50, optimistic scenario $9.16. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Evolus Inc stock forecast for 2026?
Our estimate puts fair value at $7.33, about +8% upside versus a price of $6.81 (fairly valued). Cautious scenario $5.50, optimistic scenario $9.16. The calculation is refreshed regularly with new filings.
What is the revenue of Evolus Inc (EOLS)?
Evolus Inc reported trailing-twelve-month revenue of about $325M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Evolus Inc (EOLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evolus Inc it is $7.33 per share (as of Nov 11, 2026), against a price of $6.81.
Is Evolus Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, EOLS trades below its calculated fair value: price $6.81, fair value $7.33, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EOLS?
No. The price is what the market pays today ($6.81); the fair value is what the company's own numbers justify ($7.33). For Evolus Inc the two are $0.5200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evolus Inc worth?
The market values Evolus Inc at about $449M (market capitalisation, as of Nov 11, 2026). Per share that is $6.81; our models calculate a fair value of $7.33 per share.
What do the bullish and bearish scenarios say about EOLS?
Our models span a range for Evolus Inc: cautious scenario $5.50, base $7.33, optimistic $9.16 per share (as of Nov 11, 2026, price $6.81). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Evolus Inc (EOLS)?
Balance-sheet figures for Evolus Inc (as of Nov 11, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is EOLS from its 52-week high?
Evolus Inc trades at $6.81, about 27% below its 52-week high of $9.30 and 73% above the low of $3.94 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $7.33 is for.
Which stocks are comparable to Evolus Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evolus Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $6.81, calculated fair value $7.33 (+8%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2% above its aggregate fair value. Evolus Inc currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evolus Inc (EOLS)?
The closing price on Nov 10, 2026 was $6.81. Our estimate is $7.33, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evolus Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Evolus Inc

How large is the market capitalisation of Evolus Inc (EOLS)?
The market capitalisation of Evolus Inc is $449M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evolus Inc (EOLS)?
The price-to-sales ratio of Evolus Inc is 1.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evolus Inc (EOLS)?
Earnings per share at Evolus Inc are $−0.4800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Evolus Inc (EOLS)?
The net margin of Evolus Inc is −9.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evolus Inc (EOLS)?
The return on equity (ROE) of Evolus Inc is −18,730% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evolus Inc (EOLS)?
On an EBIT basis the return on assets of Evolus Inc is −22.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evolus Inc (EOLS)?
The operating margin of Evolus Inc is −7.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evolus Inc (EOLS)?
Revenue at Evolus Inc is growing +13.0% versus a year earlier (3y avg +26.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Evolus Inc (EOLS) generate?
The free cash flow of Evolus Inc is −$45.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Evolus Inc (EOLS) carry?
The net debt of Evolus Inc is $101M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Evolus Inc in the live analysis

One click puts Evolus Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.